AstraZeneca sees breast cancer drug Enhertu improve median overall survival
(Alliance News) - AstraZeneca PLC on Saturday said its jointly developed breast cancer drug Enhertu showed improved overall survival in a phase III trial, while its leukaemia treatment Calquence showed a sustained survival benefit in another phase III trial. Read More